echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The development of the daily news-Bayer innovative therapy treatment for type 2 diabetes reached the clinical end of Stage 3.

    The development of the daily news-Bayer innovative therapy treatment for type 2 diabetes reached the clinical end of Stage 3.

    • Last Update: 2020-07-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.07.10 Research and Development NEWS: Hengrui hepatitis B new drug HRS9950 start clinical; Jasinda ERK inhibitor JSI-1187 U.SPhase I clinical trial completed the first patient administration; FDA has accepted AstraZeneca antiplatelet therapy for Guerrero's supplementary new drug application ..We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference(click on the title, read the original text) ( Drug Research and Development) Bayer's innovative therapy to reach the clinical endpoint of Phase 3 can effectively reduce the risk of death from kidney disease Today, Bayer announced that its research therapy finerenone in the treatment of patients with type 2 diabetes in the phase 3 clinical trial FIDELIO-DKD reached the main end point of the trialHengrui hepatitis B new drug HRS9950 start clinical 9, Hengrui a week ago approved clinical class 1 new drug HRS9950 tablets start clinical, indications for chronic hepatitis BColum Pharmaceuticals KL280006 Injection Phase II Clinical Launch for the treatment of acute pain 8 days, Collum Pharmaceuticals Class 1 new drug KL280006 Injection II clinical, for the treatment of acute painKL280006 injection scantilyse for Collon Pharmaceuticals, an optional peripheral opioid receptor agonist developed with independent intellectual rights, is an opioid analgesicthe first patient administration in the U.SPhase I clinical trial of The Inda ERK inhibitor JSI-1187 completed the first patient administration on the 10th, And Tesinda announced that JSI-1187's Phase I clinical trial in the United States completed the first patient administrationJSI-1187 is an oral, highly selective ERK1/2 kinase inhibitor developed to treat tumors that carry mapK kinase pathway mutationsThe Keytruda second-line treatment of classic Hodgkin's lymphoma was fda-first review eligibility, Mershadon announced that the FDA has accepted Keytruda's supplementary biologics license application and agreed to priority review eligibility for the treatment of recurrent or refractive classic Hodgkin lymphoma adult patientsFDA approved TheAmu monotomabiosimilar hulio mylan and Concord Kirin recently jointly announced that the U.SFDA has approved Hulio, Abbvie's flagship product Humira biosimilar, for the treatment of a variety of autoimmune diseases, including rheumatoid arthritis, juvenile autoarthritis (4 years and older), psoriasis arthritis, aggressive spina, adult Crohn's disease, ulcerative colonitisTHE FDA has accepted AstraZeneca's application for a new drug for Grillo today announced that the FDA has accepted its application for additional drug for Grillo's antiplatelet therapy and has granted it priority review eligibility to be used in conjunction with aspirin to reduce subsequent strokeininins in patients with acute ischemic stroke or transient ischemiaYangsen third generation TKI lung cancer target drug declared clinical in China Today, CDE latest publicannouncement, Johnson and Johnson's Johnson's Yesen Pharmaceuticallazertinib tablets in China to declare clinical trial applications, and access to CDE acceptancedayvigo, an antagonist for both-effect appetite receptor saiper, is on the market in Hong Kong, China,! The application for a new drug, Dayvigo, has been accepted by the Hong Kong Special Administrative Region of China's Department of Health for the treatment of adult insomnia, which is characterized by difficulty falling asleep and/or maintaining sleep, the company announced recentlyHuahai Pharmaceutical Subarin capsule listing application was accepted 10 days, Huahai Pharmaceuticals Pribarin capsule 4 imitation listing application was acceptedthe first of the 2 drugs through the consistency evaluation 8, the official website of the State Drug Administration shows that there are 3 drugs through the consistency evaluation, including Shandong New Era Pharmaceuticals "Omeprazole intestinal tablets" (10 mg), China Resources Zizhu Pharmaceuticals "Miso prostoster tablets" (200 sg) for the first through the consistency evaluationTreasure Island hydrochloric acid amsulmetry injection reported on the 10th, CDE official website shows that Treasure Island Pharmaceuticals hydrochloric acid ammonia broso injection 4 class imitation listing application was acceptedResearch and Development Partnership, The Canadian Clinical Biopharmaceutical Company Zymeworks has announced that it has signed a new licensing agreement with long-term partner Mercadon worth more than $900 million, granting the latter the right to develop multispecific antibody treatment candidates using its Azymetric ™ and EFECT ™ platformsSanofi, together with Kymera, announced today that it has partnered with Sanofi to develop a multi-project partnership to jointly develop and commercialize "first-in-class" protein degradation therapy for IRAK4 to treat immuno-inflammatory diseasesthe two companies will also collaborate on a second project that is in the early stages of development.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.